IKT (Inhibikase Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 28, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-05-28), Inhibikase Therapeutics's share price is $1.77. Inhibikase Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.34. Hence, Inhibikase Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Inhibikase Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

IKT's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.33
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Inhibikase Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.05. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.34.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 44.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -35.60% per year.

During the past 7 years, Inhibikase Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 44.40% per year. The lowest was -173.00% per year. And the median was -53.80% per year.

Inhibikase Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Inhibikase Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics Price-to-Operating-Cash-Flow Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Inhibikase Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inhibikase Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Inhibikase Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Inhibikase Therapeutics Price-to-Operating-Cash-Flow Calculation

Inhibikase Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.77	/	-1.343
	=

Inhibikase Therapeutics's Share Price of today is $1.77.
Inhibikase Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Inhibikase Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339

Website

https://www.inhibikase.com

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Executives

Paul C Grint	director	7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman	director	9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman	director	256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner	director, 10 percent owner, officer: President and CEO	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli	officer: Cheif Financial Officer
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman	10 percent owner	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339